Drugs / TriAdeno vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07574541 | Jul 2026 → Jun 2027 expected | adenocarcinoma, prostate cancer | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TriAdeno vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07574541 ↗ |
| Modality | Vaccine | “A new trivalent vaccine which targets 3 tumor associated antigens (PSA, brachyury, and MUC-1)” NCT07574541 ↗ |
| Route | Subcutaneous | “The TriAdeno vaccines will be administered subcutaneously (SC)” NCT07574541 ↗ |